查找临床试验
已按「白血病」检索，对应国际通用词 leukemia
共找到 417 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 22:08，每 5 分钟自动同步Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
China
年龄 3 Years – 25 Years
Hebei Senlang Biotechnology Inc., Ltd.
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
China
年龄 18 Years – 不限
Institute of Hematology & Blood Diseases Hospital, China
Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
China
年龄 14 Years – 54 Years
Institute of Hematology & Blood Diseases Hospital, China
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
China
年龄 18 Years – 不限
Ascentage Pharma Group Inc.
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
China
年龄 3 Years – 21 Years
Chongqing Precision Biotech Co., Ltd
International Chronic Myeloid Leukemia Pediatric Study
Australia、Austria、Belarus、Belgium、Brazil 等 12 国
年龄 不限 – 18 Years
Poitiers University Hospital
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
United States、Australia、Belgium、Brazil、Canada 等 12 国
年龄 18 Years – 不限
Merck Sharp & Dohme LLC
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
China
年龄 18 Years – 不限
Institute of Hematology & Blood Diseases Hospital, China
Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
China
年龄 18 Years – 70 Years
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
China
年龄 18 Years – 不限
Sunshine Lake Pharma Co., Ltd.
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
China
年龄 18 Years – 70 Years
Affiliated Hospital of Nantong University
Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy
China
年龄 18 Years – 不限
Peking University First Hospital